Is this you? Create Your Porfile
Avatar

Geraldine Helen O'Sullivan Coyne

National Institutes of Health

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Geraldine Helen O'Sullivan Coyne is active.

Explore More

Publication

Featured researches published by Geraldine Helen O'Sullivan Coyne.

Journal of Clinical Oncology | 2014

Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.

Christopher R. Heery; Geraldine Helen O'Sullivan Coyne; Ravi A. Madan; Jeffrey Schlom; Anja von Heydebreck; Jean-Marie Cuillerot; Helen Sabzevari; James L. Gulley

Journal of Clinical Oncology | 2015

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.

Harpreet Singh; Ravi A. Madan; William L. Dahut; Geraldine Helen O'Sullivan Coyne; Myrna Rauckhorst; Sheri McMahon; Christopher R. Heery; Jeffrey Schlom; James L. Gulley

Journal of Clinical Oncology | 2017

Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.

Shivaani Kummar; Khanh Do; Geraldine Helen O'Sullivan Coyne; Baris Turkbey; Paul S. Meltzer; Eric C. Polley; Yvonne Horneffer; Lamin Juwara; Ramya Antony; Peter L. Choyke; Sandra A. Mitchell; Lee J. Helman; Alice Chen; James H. Doroshow

Journal of Clinical Oncology | 2016

Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.

Geraldine Helen O'Sullivan Coyne; Shivaani Kummar; Khanh Tu Do; Peter L. Choyke; Baris Turkbey; Eric C. Polley; Yvonne Horneffer; Lamin Juwara; Rasa Vilimas; Robert S. Meehan; Lee J. Helman; James H. Doroshow; Alice P. Chen

Journal of Clinical Oncology | 2016

A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.

Robert S. Meehan; Geraldine Helen O'Sullivan Coyne; Shivaani Kummar; Jerry M. Collins; Larry D. Anderson; Jennifer Zlott; Lamin Juwara; Naoko Takebe; Richard Piekarz; Howard Streicher; Elad Sharon; Barbara A. Conley; Larry Rubinstein; Deborah Wilsker; Angie B. Dull; Katherine V. Ferry-Galow; Robert J. Kinders; James H. Doroshow; Alice P. Chen

Journal of Clinical Oncology | 2018

Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers.

Geraldine Helen O'Sullivan Coyne; Kevin C. Conlon; Naoko Takebe; Howard Streicher; Mary Flanagan Quinn; Ashley Bruns; Tony Navas; Ralph E. Parchment; Larry Rubinstein; Elad Sharon; James H. Doroshow; Thomas A. Waldmann; Alice P. Chen

Journal of Clinical Oncology | 2018

Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.

Geraldine Helen O'Sullivan Coyne; Khanh Tu Do; Shivaani Kummar; Naoko Takebe; Mary Flanagan Quinn; Sarina Anne Piha-Paul; Ashley Bruns; Lamin Juwara; Elad Sharon; Richard Piekarz; Howard Streicher; Larry Rubinstein; Deborah Wilsker; Robert J. Kinders; Ralph E. Parchment; E. Levy; Austin Doyle; James H. Doroshow; Alice P. Chen

Journal of Clinical Oncology | 2018

Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptor–positive solid tumors including desmoid and gynecologic tumors.

Naoko Takebe; Geraldine Helen O'Sullivan Coyne; Shivaani Kummar; Joel M. Reid; Richard Piekarz; Lyndsay Harris; Lamin Juwara; Mary Flanagan Quinn; Nancy Moore; Peter L. Choyke; Esther Mena; Liza Lindenberg; Frank I. Lin; Matthew P. Goetz; Renee M. McGovern; Howard Streicher; Joseph M. Covey; Jerry M. Collins; James H. Doroshow; Alice P. Chen

Journal of Clinical Oncology | 2018

Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.

Naoko Takebe; Geraldine Helen O'Sullivan Coyne; Shivaani Kummar; Khanh Do; Ashley Bruns; Lamin Juwara; Mary Flanagan Quinn; Lyndsay Harris; Richard Piekarz; Sheila A. Prindiville; Elad Sharon; Howard Streicher; Ganesh Mugundu; Jiuping Jay Ji; Deborah Wilsker; Robert J. Kinders; Larry Rubinstein; James H. Doroshow; Alice P. Chen

Journal of Clinical Oncology | 2017

Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors.

Geraldine Helen O'Sullivan Coyne; Shivaani Kummar; Robert S. Meehan; Lamin Juwara; Richard Piekarz; Elad Sharon; Howard Streicher; Barbara A. Conley; Naoko Takebe; Lyndsay Harris; Austin Doyle; Mary Flanagan Quinn; Larry Rubinstein; Deborah Wilsker; Robert J. Kinders; E. Levy; James H. Doroshow; Alice P. Chen

Explore More

Collaboration

Dive into the Geraldine Helen O'Sullivan Coyne's collaboration.

Top Co-Authors
Avatar

James H. Doroshow

National Institutes of Health

View shared research outputs
Top Co-Authors
Avatar

Alice P. Chen

National Institutes of Health

View shared research outputs
Top Co-Authors
Avatar

Shivaani Kummar

Stanford University

View shared research outputs
Top Co-Authors
Avatar

Lamin Juwara

Science Applications International Corporation

View shared research outputs
Top Co-Authors
Avatar

Larry Rubinstein

National Institutes of Health

View shared research outputs
Top Co-Authors
Avatar

Howard Streicher

National Institutes of Health

View shared research outputs
Top Co-Authors
Avatar

Naoko Takebe

National Institutes of Health

View shared research outputs
Top Co-Authors
Avatar

Robert S. Meehan

National Institutes of Health

View shared research outputs
Top Co-Authors
Avatar

Mary Flanagan Quinn

Case Western Reserve University

View shared research outputs
Top Co-Authors
Avatar

Richard Piekarz

National Institutes of Health

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge